Bioxyne Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
992.40
958.50
1,353.60
3,875.90
3,309.90
Total Accounts Receivable
141.10
191.60
294.20
485.80
706.90
Inventories
-
-
-
101.30
628.70
Other Current Assets
40.70
38.00
36.90
51.00
89.20
Total Current Assets
1,174.20
1,188.00
1,684.70
4,514.00
4,734.60
Net Property, Plant & Equipment
-
-
-
2.90
160.80
Total Investments and Advances
325.00
325.00
325.00
-
-
Intangible Assets
-
-
-
223.40
155.10
Total Assets
1,499.20
1,513.00
2,009.70
4,740.30
5,050.40
Accounts Payable
238.20
130.70
215.10
335.20
416.50
Other Current Liabilities
189.00
98.60
243.30
274.40
312.40
Total Current Liabilities
427.30
229.40
458.40
609.60
728.90
Total Liabilities
427.30
229.40
458.40
609.60
728.90
Common Equity (Total)
1,071.90
1,283.70
1,551.30
4,130.70
4,321.50
Total Shareholders' Equity
1,071.90
1,283.70
1,551.30
4,130.70
4,321.50
Total Equity
1,071.90
1,283.70
1,551.30
4,130.70
4,321.50
Liabilities & Shareholders' Equity
1,499.20
1,513.00
2,009.70
4,740.30
5,050.40

About Bioxyne

View Profile
Address
50 Clarence Street
Sydney New South Wales (NSW) 2000
Australia
Employees -
Website http://www.bioxyne.com
Updated 07/08/2019
Bioxyne Ltd. focuses on the development of immune health and immunotherapeutic products. It manufactures, markets, and distributes over-the-counter dietary supplement probiotic products, such as Lactobacillus Fermentum PCC. It operates through the Probiotics and Others segments.